Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones

• US 7,683,095 B2
• Filed: 05/26/2004
• Issued: 03/23/2010
• Est. Priority Date: 10/06/1998
• Status: Expired due to Term

• Current Assignee: Interhealth Nutraceuticals
• Original Assignee: KGK Synergize Incorporated, United States Department Of Agriculture
• Inventors: Manthey, John A., Guthrie, Najla, Kurowska, Elzbieta Maria
• Primary Examiner(s): Jiang; Shaojia Anna
• Assistant Examiner(s): OLSON, ERIC
• Application Number:
  US10/854,063
• Publication Number:
  US 20040214882A1
• Time in Patent Office: 2,127 Days
• Field of Search: 514/456, 514/458, 514/457, 549/399, 549/403, 424/736
• US Class Current: 514/456
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/35 having six-membered rings with one oxygen as the only ring hetero atom
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658

Abstract

Compositions and methods for the treatment, reduction and/or prevention of cardiovascular diseases and disorders are described. Individuals at high risk for developing or having cardiovascular disease or disorder may be treated with an effective dose of a polymethoxyflavone including limocitrin derivatives, quercetin derivatives, naturally occurring polymethoxyflavones, tocotrienols, and mixtures of these compounds.

Claims

1. A method of lowering serum cholesterol, Apo B or LDL cholesterol comprising orally administering to a mammal having elevated levels of serum cholesterol, Apo B or LDL cholesterol an oral pharmaceutical dosage form selected from the group consisting of a tablet or a capsule, said dosage form comprising at least one pharmaceutically acceptable excipient and a combination of

(a) at least one limocitrin derivative selected from the group consisting of limocitrin-3,7,4′

-trimethylether;

limocitrin-3,5,7,4′

-tetramethylether; and

limocitrin-3,7,4′

-trimethylether-5-acetate, and

(b) at least one quercetin derivative selected from the group consisting of quercetin tetramethylether;

quercetin 3,5-dimethylether-7,3′

,4′

-tribenzylether;

quercetin pentamethylether;

quercetin-5,7,3′

,4′

-tetramethylether-3-acetate; and

quercetin-5,7,3′

,4′

-tetramethylether;

to provide about 1-1000 mg/day limocitrin derivative and about 1-1000 mg/day quercetin derivative.

2. The method of claim 1, wherein the dosage form further comprises at least one tocotrienol and wherein the administration provides an amount of said dosage form to provide about 1-1000 mg/day tocotrienol.

3. The method of claim 1, wherein the tablet or capsule contains a predetermined amount of the mixture as solids, gelatins, suspensions or emulsions.

4. The method of claim 1, wherein the pharmaceutical acceptable excipient is a gel phase carrier.

5. The method of claim 1, wherein the pharmaceutically acceptable excipient is selected from the group consisting of calcium carbonate, calcium phosphate, a sugar, a starch, a cellulose derivative, gelatin and a polymer.

6. The method of claim 1, wherein the dosage form further comprises at least one polymethoxyflavone and wherein the administration provides an amount of said dosage form to provide about 1-1000 mg/day polymethoxyflavone.

7. The method of claim 1, wherein said mammal is a human.